Overview

Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)

Status:
Completed

Trial end date:
2020-07-24

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to evaluate the efficacy and safety of a single dose of RPH-104 (80 mg) or OKZ (64 mg) compared to placebo in addition to standard therapy in patients with severe SARS-CoV-2 infection (COVID-19) at Day 15 of the study

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

R-Pharm International, LLC

Collaborators:

Data Management 365 LLC
K-Research, LLC